Q4 2025 Earnings Presentation February 18, 2026 Xandra Velzeboer Netherlands Short Track Speed Skating Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, re ...

The company is repositioning itself from a traditional weight loss focus to a broader metabolic health framework to address fundamental metabolic dysfunction rather than just symptoms. Management introduced 'metabolic synchronization,' a science-driven approach designed to reverse metabolic dysfunction by reducing visceral fat while preserving 98% of lean mass. Performance in Q4 2025 showed the first year-over-year increase in coach productivity since mid-2022, rising 6% as coaches adopt the new metab ...

Core Insights - The company is transitioning from a weight loss focus to a broader metabolic health approach, termed "Metabolic Synchronization," in response to industry disruptions and changing consumer expectations [2][5][21] Financial Performance - Medifast reported a fourth-quarter revenue decline of 36.9% to $75.1 million, with a net loss of $18.1 million, influenced by a $12.1 million non-cash valuation allowance [4][10][12] - The company ended 2025 with $167.3 million in cash and no debt, and it reinstated 2026 revenue guidance of $270 million to $300 million, anticipating profitability improvements starting in Q4 2026 [4][16] Coach Productivity and Engagement - Despite a 40.6% decline in active earning coaches to approximately 16,100, average revenue per active coach increased by 6.2% to $4,664, indicating early signs of improved coach productivity [5][11] - Initiatives to enhance coach productivity include higher levels of coach-led opportunity meetings and training activities, with a notable percentage of coaches reaching executive director rank [6][7] Leadership Transition - CEO Dan Chard will step down on June 1, 2026, with President Nick Johnson expected to take over, while Chard will remain as chairman [2][5] Market Dynamics - The company is adapting to the impact of GLP-1 medications on the weight loss industry, with a focus on clients who may seek alternatives after discontinuing these medications [10][20] - Medifast's messaging around visceral fat reduction and lean mass preservation is resonating with consumers focused on body composition [20]

Medifast ® Q4 2025 Earnings Supplement 1 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expect" or other similar words or the negative of such terminology. ...

Key Takeaways MED is expected to post a 40.5% revenue drop and a loss of 76 cents per share in Q4. Medifast's shrinking OPTAVIA coach base and GLP-1 competition may have hurt sales volumes. MED's Premier pricing, auto-ship retention gains and strong balance sheet may cushion results. Medifast, Inc. (MED) is likely to witness a top and bottom-line decline when it reports fourth-quarter fiscal 2025 earnings on Feb. 17, after market close. The Zacks Consensus Estimate for revenues is pegged at $70.8 million, i ...

Core Insights - Prenetics Global Limited will release its financial results for Q4 and full year 2025 on February 18, 2026, before market open [1] - An earnings conference call will be held on the same day at 10:00 a.m. Eastern Time, including a Q&A session with analysts [1][2] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [3] - IM8 has rapidly grown, surpassing $100 million in annualized revenue within 11 months and is now available in over 30 countries [3] - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements and is NSF Certified for Sport, non-GMO, vegan, and free from common allergens [4]

Core Viewpoint - Natural Health Trends Corp is conducting its Fourth Quarter and Full Year 2025 Earnings Conference Call, indicating a focus on financial performance and future outlook [2]. Group 1: Company Overview - The call is led by Michelle Glidewell, Senior Manager of NHT Global Corp, highlighting the company's leadership structure [2]. - Chris Sharng, President of Natural Health Trends, is also involved in the call, suggesting a collaborative approach to discussing the company's performance [4]. Group 2: Forward-Looking Statements - The company acknowledges that statements made during the call may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, indicating a focus on future results and potential uncertainties [3]. - Actual results may differ materially from those anticipated due to various factors, emphasizing the importance of understanding the risks associated with forward-looking statements [3].

Financial Data and Key Metrics Changes - In the 4th Quarter, revenue was $9.7 million, a 3% increase from $9.5 million in the 3rd Quarter, but a 10% decline from $10.8 million in the 4th Quarter of the previous year [6] - Gross profit margin was 72.9% in the 4th Quarter, down from 74.2% in the same quarter last year, primarily due to inventory write-offs [7] - Net loss for the 4th Quarter was $588,000, or $0.05 per diluted share, compared to net income of $176,000, or $0.02 per diluted share in the 4th Quarter of 2024 [8] Business Line Data and Key Metrics Changes - Reorders as a percentage of total orders increased in the largest market compared to 2024, and sales of Q-rated product bundles rose 10% for the Full Year [3] - The company saw growth in Taiwan and Peru during the 4th Quarter, with Japan and Colombia achieving strong increases throughout the year [3] Market Data and Key Metrics Changes - Revenue in the primary market of Greater China increased by 2% compared to the 3rd Quarter [6] Company Strategy and Development Direction - The company is focusing on improving operational efficiency through restructuring initiatives, including relocating 40% of product sourcing from America to East Asia to reduce tariff uncertainty [4] - The company plans to celebrate its 25th anniversary in 2026 with special programs and events, aiming to leverage this milestone for renewed momentum [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to support goals in an evolving global environment, emphasizing a strong product portfolio and renewed focus on execution [5] - The company expects to realize significant cost savings of approximately $1.5 million during 2026, positioning itself towards profitability and improved performance [10] Other Important Information - Total cash, cash equivalents, and marketable securities were $28.9 million at December 31, down from $32 million at September 30, primarily due to dividend payments and cash used in operations [9] - The board of directors declared a quarterly cash dividend of $0.10 per share, payable on February 27 to stockholders of record as of February 17 [10] Summary of Q&A Session - The call concluded without a Q&A session, as indicated by the operator's closing remarks [12]

Financial Data and Key Metrics Changes - In the 4th Quarter, revenue was $9.7 million, a 3% increase from $9.5 million in the 3rd Quarter, but a 10% decline from $10.8 million in the 4th Quarter of the previous year [6] - Gross profit margin was 72.9% in the 4th Quarter, down from 74.2% in the same quarter last year, primarily due to inventory write-offs [7] - Net loss for the 4th Quarter was $588,000, or $0.05 per diluted share, compared to net income of $176,000, or $0.02 per diluted share in the 4th Quarter of 2024 [8] Business Line Data and Key Metrics Changes - Reorders as a percentage of total orders increased in the largest market compared to 2024, and sales of curated product bundles rose 10% for the Full Year [3] - Commissions expenses as a percentage of net sales for the 4th Quarter were 40.3%, down from 41.9% a year ago [7] - Selling general and administrative expenses were $3.8 million for the 4th Quarter, a slight decrease from $3.9 million a year ago [8] Market Data and Key Metrics Changes - Revenue in the primary market of Greater China increased by 2% compared to the 3rd Quarter, with notable growth in Taiwan and Peru during the 4th Quarter [6][3] - Japan and Colombia achieved strong increases throughout the year, contributing positively to overall performance [3] Company Strategy and Development Direction - The company is focusing on improving operational efficiency through restructuring initiatives, including relocating 40% of product sourcing to East Asia to reduce tariff uncertainty [4] - The company anticipates realizing approximately $1.5 million in annualized cost savings during 2026, which is expected to enhance profitability and performance [10] - Celebrating its 25th anniversary in 2026, the company plans special programs and events to leverage this milestone for renewed momentum [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to support goals in an evolving global environment, emphasizing a strong product portfolio and renewed focus on execution [5] - The management highlighted the importance of member engagement and ongoing demand for core products as key drivers for future growth [3] Other Important Information - Total cash, cash equivalents, and marketable securities were $28.9 million at the end of the year, down from $32 million at the end of the previous quarter [9] - The company paid out $9.2 million in dividends for the full year of 2025, reaffirming its commitment to returning capital to stockholders [9][10] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.

Core Insights - Earth Science Tech Inc. has engaged IBN to enhance its corporate communications strategy, aiming to improve investor awareness and outreach [1][4]. Company Overview - Earth Science Tech operates as a strategic holding company focused on a diversified portfolio within regulated healthcare markets, emphasizing execution, compliance, and disciplined scaling [2]. - The company prioritizes hands-on operational oversight to build sustainable revenue streams and long-term shareholder value, rather than passive asset ownership [2]. Business Strategy - The company's diversified operations include licensed pharmaceutical compounding, digital health and telemedicine platforms, specialty healthcare services, and complementary assets [3]. - Earth Science Tech maintains direct control over day-to-day operations through wholly owned and majority-owned subsidiaries, allowing flexibility in capital and resource allocation [3]. Partnership with IBN - IBN will leverage its extensive investor-focused distribution network, which includes over 5,000 syndication outlets and various media channels, to increase awareness for Earth Science Tech [4][5]. - IBN has over 20 years of experience and a large audience, positioning it to effectively reach investors, journalists, and the general public [5]. Additional Information - Earth Science Tech's portfolio includes subsidiaries such as RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, focusing on health and wellness [5].